Barclays
IRWD icon

Barclays’s Ironwood Pharmaceuticals IRWD Stock Holding History

Barclays’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-280,800
Closed -$2.45M – 5083
2024
Q1 		$2.45M Buy
280,800
+165,000
+142% +$2M ﹤0.01% 2399
2023
Q4 		$1.32M Sell
115,800
-48,600
-30% -$481K ﹤0.01% 3233
2023
Q3 		$1.58M Buy
+164,400
New +$1.61M ﹤0.01% 2029
2017
Q4 		– Sell
-1,194
Closed -$16K – 7001
2017
Q3 		$16K Buy
+1,194
New +$16.4K ﹤0.01% 5906
2016
Q2 		– Sell
-119,400
Closed -$1M – 6461
2016
Q1 		$1M Buy
+119,400
New +$985K ﹤0.01% 2521
2013
Q3 		– Sell
-17,910
Closed -$149K – 7505
2013
Q2 		$149K Buy
+17,910
New +$217K ﹤0.01% 5455

Other funds holding IRWD

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Barclays's IRWD Position: Q1 2026 in Review

Barclays reduced its Ironwood Pharmaceuticals (IRWD) stake by 77% in Q1 2026, selling an estimated $1.24M and leaving 89,970 shares worth $316K. The position accounts for ﹤0.01% of the portfolio, ranked #3450.

Barclays first reported a position in IRWD in Q2 2013 and has held it in 52 quarters since. The position peaked at $6.32M in Q4 2023. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

  • Barclays held 89,970 shares of Ironwood Pharmaceuticals worth $316K as of Q1 2026.
  • Barclays sold 302,934 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $1.24M.
  • Ironwood Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3450 holding.
  • Barclays first reported a position in Ironwood Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Barclays's Ironwood Pharmaceuticals position peaked at $6.32M in Q4 2023.
  • 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.